Analysts predict triple-bagger potential 💰

They just changed the game…                                                                                                                                                                                                                                                                                                                                                                                                                 March 18, 2024 Analysts predict triple-bagger potential 💰 They just changed the game… *Sponsored by Sica Media Analysts Predict a TRIPLE (or more!) for this Budding Biotech Superstar! While I am getting pretty bearish on tech stocks right now, biotechs continue to be a beacon of light for the market. There doesn’t seem to be a day that goes by where I don’t see a few stocks in this sector popping off for big gains. One of the biggest keys to finding a breakout is to simply look at stocks that have recently gone against the trend and made a big move. It is usually impossible to catch the first move, but I find if I am patient, I have much better luck catching at least a piece of the second move. And that is what I think we could see setting up right now. Pull up Actinium Pharmaceuticals (ATNM) on your screen right away. I want to show you what could be a very urgent setup forming. As you can see, ATNM was in a consolidation channel for a while in the $5-6 range. One of the things I learned early on as a trader is that “triple tops never are.” This means that when a stock hits a resistance point three times like we did with ATNM recently, the stock almost always wants to break though that level. I was watching this happen, but I was hesitant to pull the trigger on it.  Too bad for me, because I just watched another biotech on my watchlist take off without me. This time, the stock made a 60% move in about two week’s time, as it rallied to nearly $9 at one point. Like I said, one of my favorite strategies is to wait for the second move. Nothing is ever certain with trading, of course, but I think the second wave is a lot more predictable. My favorite way to play this is to wait for the stock to trade back above the 20-MA resistance line I have on the chart above. We just started to see that happen on Friday. If things go well today, I think we could have ignition again soon! This is one of those stories that you won’t hear on TV, but the “big boys” are starting to take notice of it, especially after ATNM dropped [blockbuster news]( on Feb 26th. Read that news, because it was a life-changing moment for ATNM. While there wasn’t a ton of analysts looking at this stock prior to then, look at how quickly everyone jumped on the bandwagon and started to slap [huge price targets]( on the stock and “Strong Buy” ratings… After that news last month, the average price target is over 300% higher from current price levels. Do you think this one has room to run?! While ATNM isn’t widely followed by a lot of retail traders right now, it does have a growing “fanbase,” of [big institutions]( that have been accumulating shares. Blackrock…. Vanguard… Morgan Stanley, etc… These guys know something, and they have been loading up on shares according to the last report at the end of 2023. Can you imagine what these holdings are going to look like at the next filing soon? I’m betting some new whales show up on this list. I also saw that a prominent publication [just listed]( ATNM as one of their top stock ideas on the “verge of a clinical victory.” For some background, Actinium Pharmaceuticals, Inc. (ATNM) is a late-stage biopharmaceutical company developing targeted radiation treatments for cancer. The company has a big portfolio of intellectual property, with more than 220 patents and patent applications worldwide. At the core of its strategy is a nuclear isotope called Actinium-225, which the company [describes]( as “the most powerful medical grade radioisotope known to man.” Critically, “its power is emitted over a short distance of a few millimeters making it ideal for targeted radiotherapy.” The company’s therapies deploy this weapon directly to cancer cells using what it amusingly calls Antibody Warhead Enabling (AWE) technology. The idea is to target cancer cells specifically, like a heat-seeking missile, unlike prevailing radiation therapies which have a much more systemic impact. This strategy has possible indications for many kinds of cancers, but ATNM put it fully to the test in a recently-completed Phase III trial for older patients with relapsed or refractory acute myeloid leukemia (AML). The results were nothing short of “incredible”… In the control arm of the trial, no patients survived beyond one year, despite receiving the usual treatments. For the patients who received Iomab-B — one of the company’s proprietary radiopharmaceuticals — 20.1% survived one year, and 11.5% were alive after two years, a duration the company [says]( is “highly indicative of long-term outcomes including potential cure.” A two-year survival rate of 11.5% may not seem great, but this is a particularly nasty form of cancer, so this therapy has the potential to become the new standard of care in these patients. It’s because of Iomab-B’s potential to fill an unmet medical need that the FDA granted it an [orphan drug designation]( in 2016. Eight years later, that tree is bearing fruit. ATNM intends to file a Biologics License Application (BLA) with the FDA for Iomab-B later this year, setting the stage for commercialization. While this could undoubtedly be a boon for the company, in my view the success of the Iomab-B trial is best seen as a proof-of-concept for the company’s targeted radiotherapies… And indeed, ATNM has a much broader [product pipeline]( and says its therapies could apply to solid tumors in addition to blood cancers. The company also [says]( that its whopping $83.0 million cash pile is projected to fund operations through 2025. Simply incredible stuff here. Right now, I want you to do your own due diligence to get ready for today. Let me remind you to always approach your trading in a responsible manner. Never trade with more than you can afford to lose, and always have a well-thought-out game plan that takes your personal risk tolerance into consideration. Bottom line: ATNM represents one of the biggest opportunities I have come across in a long time. The recent news was a game-changing event from the company, and I think it is going to transform the trajectory from here.  With analysts suggesting the stock could rise 300% (or more!) from these levels, I think it is a no-brainer to at least do your homework and see why traders are getting so excited about this idea right now. If the price chart cooperates, we could be on the verge of something special today. To Your Success, 👊 Make sure you are getting my mobile text alerts –  text “RAGE” to 1-(888) 404-5747 to get all of my latest HOT STOCK ideas delivered right to your phone (make sure you put the “1” at the front!). Don’t miss out! *Sponsored content/paid advertisement. This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results. Questions or concerns about our products? Email Support@ragingbull.com © Copyright 2022, RagingBull DISCLAIMERS *PAID ADVERTISEMENT.  Raging Bull has currently been paid seventeen thousand five hundred dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising Actinium Pharmaceuticals, Inc from a period beginning on for a one day marketing program. The third party, Company, or their affiliates may own and likely wish to liquidate shares of the Company at or near the time you receive this advertisement, which has the potential to hurt share prices. This advertisement and other marketing efforts, including alerts, may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of Actinium Pharmaceuticals, Inc, increased trading volume, and possibly an increased share price of Actinium Pharmaceuticals, Inc’s securities, which may or may not be temporary and decrease once the marketing arrangement has ended. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of the issuance of this advertisement, the owners of Raging Bull do not hold a position in Actinium Pharmaceuticals, Inc, though they reserve the right to buy or sell shares in the covered company at any time following the dissemination of this communication. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for educational and informational purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, Raging Bull cannot guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision. SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. A portion of our business is engaged in the marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. A portion of RagingBull’s business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our websites, email, SMS, push notifications. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently, companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the corporate awareness program ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is not currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at https: // www. Sec. gov/ edgar/searchedgar /companysearch TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied. [tw]( Update your email preferences or unsubscribe [here]( © 2024 Bullseye Trades 62 Calef Hwy. #233 Lee, NH 03861, United States of America